Turbogen Ltd. (TRBG) announced that its ordinary shares have been approved for listing on the Nasdaq Capital Market. Trading on Nasdaq begins on August 31, 2026 at market open under the ticker symbol “TRBG”. Turbogen will also maintain its existing listing on the Tel Aviv Stock Exchange under the symbol “TURB.” Company leadership states that the Nasdaq listing is expected to expand its global reach, increase visibility among investors and business partners, and improve liquidity in its shares.
Turbogen Ltd. (TRBG) reports the initial beneficial ownership of Chief Operating Officer Nir Ziv. He directly holds 130,756 ordinary shares, comprising 24,988 shares and RSUs that each convert into one ordinary share. These include RSU grants of 10,384 units from December 31, 2023, 10,384 units from March 30, 2025, and 85,000 units from April 29, 2026, with portions vesting in 6.25% quarterly installments. He also holds employee share options over 201,017 ordinary shares in total, with exercise prices of $3.45, $1.79, $3.39, and $6.18 per share and expirations between 2033 and 2036; some option grants are already fully vested while later grants begin vesting in 2024 and 2027.
Turbogen Ltd. (TRBG) director Gafni Ziv filed an initial ownership report detailing current equity interests. Ziv holds 81,676 Ordinary shares directly. In addition, Ziv holds options over 30,177 Ordinary shares with an exercise price of $2.99 per share, expiring on March 9, 2032. As of August 25, 2026, 20,118 of these options are fully vested and none have been exercised.
Turbogen Ltd. (TRBG) reported the initial holdings of Chief Executive Officer Yaron Gilboa in a Form 3. Gilboa holds 683,906 ordinary shares directly, consisting of ordinary shares and time-vesting restricted share units. He also holds several option grants to acquire additional ordinary shares at exercise prices between $1.29 and $6.18 per share with expirations from 2029 through 2036, all reported as unexercised as of late August 2026.
Turbogen Ltd. (TRBG) reported the initial equity holdings of Chief Financial Officer Hashai Neta Zruya. As of August 25, 2026, she beneficially holds 176,875 ordinary shares, including granted restricted share units, and two option grants over an additional 235,000 ordinary shares at fixed exercise prices.
The 176,875 ordinary shares position consists of 21,875 shares, 70,000 RSUs granted on October 5, 2025 and 85,000 RSUs granted on April 29, 2026. The 2025 RSUs vest 31.25% initially and 6.25% quarterly thereafter, with 21,875 vested and 48,125 unvested as of August 25, 2026. The 2026 RSUs vest in 6.25% quarterly installments, all 85,000 unvested as of that date. Option grants cover 150,000 shares at $5.54 per share expiring October 5, 2035 and 85,000 shares at $6.18 per share expiring April 29, 2036; footnotes state none of these options have been exercised.
Turbogen Ltd. (TRBG) reported that director Shitrit Idan Ben holds options to purchase 30,177 ordinary shares. These options were granted on March 9, 2025, at an exercise price of $2.99 per share and expire on March 9, 2032.
The grant vests in three equal installments of 33.3% beginning March 9, 2025. As of August 25, 2026, 20,118 options are fully vested, and none have been exercised into ordinary shares.
Turbogen Ltd. (TRBG) reported the initial beneficial ownership of securities by director Levy Ethy. Ethy holds share options giving the right to buy 30,177 ordinary shares, granted on March 9, 2025, that vest in three equal installments of 33.3% beginning March 9, 2025. As of August 25, 2026, 20,118 options are fully vested and none have been exercised into ordinary shares. The options carry an exercise price of NIS 8.95 per share, which for this report was converted using an exchange rate of NIS 2.994 to USD $1.00, resulting in an exercise price of $2.99 per share. The options are held directly, relate to 30,177 underlying ordinary shares, become exercisable beginning March 29, 2025, and expire on March 9, 2032.
Turbogen Ltd. (TRBG) reported the initial holdings of director Eli Zooker. He holds a share option to acquire 30,177 ordinary shares at an exercise price of $2.99 per share, granted on March 9, 2025 and expiring on March 9, 2032. The options vest in three equal installments of 33.3% beginning March 9, 2025; as of August 25, 2026, 20,118 options are fully vested and none have been exercised.
Turbogen Ltd. (TRBG) reported the initial equity holdings of director Deri David. He holds 36,123 ordinary shares directly and options over 30,177 ordinary shares.
The options were granted on March 9, 2025, with an exercise price of NIS 8.95 per share, which for this report was converted to $2.99 per share using an exchange rate of NIS 2.994 to $1.00 as of August 24, 2026. They vest in three equal installments of 33.3% beginning March 9, 2025; as of August 25, 2026, 20,118 options are fully vested and none have been exercised into ordinary shares.
Turbogen Ltd. (TRBG) filed an initial statement of beneficial ownership for director Alex Katz. The filing reports that Katz holds 1,134,602 ordinary shares of Turbogen Ltd. directly after the reported event. No specific purchase or sale transaction, price information, or derivative securities are disclosed.